C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates

Robin Schmitz, Zachary W. Fitch, Paul M. Schroder, Ashley Y. Choi, Miriam Manook, Janghoon Yoon, Mingqing Song, John S. Yi, Sanjay Khandelwal, Gowthami M. Arepally, Alton B. Farris, Edimara S. Reis, John D. Lambris, Jean Kwun () and Stuart J. Knechtle ()
Additional contact information
Robin Schmitz: Duke University School of Medicine
Zachary W. Fitch: Duke University School of Medicine
Paul M. Schroder: Duke University School of Medicine
Ashley Y. Choi: Duke University School of Medicine
Miriam Manook: Duke University School of Medicine
Janghoon Yoon: Duke University School of Medicine
Mingqing Song: Duke University School of Medicine
John S. Yi: Duke University
Sanjay Khandelwal: Duke University School of Medicine
Gowthami M. Arepally: Duke University School of Medicine
Alton B. Farris: Emory University School of Medicine
Edimara S. Reis: University of Pennsylvania
John D. Lambris: University of Pennsylvania
Jean Kwun: Duke University School of Medicine
Stuart J. Knechtle: Duke University School of Medicine

Nature Communications, 2021, vol. 12, issue 1, 1-11

Abstract: Abstract Sensitized kidney transplant recipients experience high rates of antibody-mediated rejection due to the presence of donor-specific antibodies and immunologic memory. Here we show that transient peri-transplant treatment with the central complement component C3 inhibitor Cp40 significantly prolongs median allograft survival in a sensitized nonhuman primate model. Despite donor-specific antibody levels remaining high, fifty percent of Cp40-treated primates maintain normal kidney function beyond the last day of treatment. Interestingly, presence of antibodies of the IgM class associates with reduced median graft survival (8 vs. 40 days; p = 0.02). Cp40 does not alter lymphocyte depletion by rhesus-specific anti-thymocyte globulin, but inhibits lymphocyte activation and proliferation, resulting in reduced antibody-mediated injury and complement deposition. In summary, Cp40 prevents acute antibody-mediated rejection and prolongs graft survival in primates, and inhibits T and B cell activation and proliferation, suggesting an immunomodulatory effect beyond its direct impact on antibody-mediated injury.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25745-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25745-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25745-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().